Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Ageno W, et al. Among authors: monje d. Lancet Haematol. 2016 Jan;3(1):e12-21. doi: 10.1016/S2352-3026(15)00257-4. Epub 2015 Dec 8. Lancet Haematol. 2016. PMID: 26765643
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
Mantovani LG, Haas S, Kreutz R, Folkerts K, Gebel M, Monje D, Schneider J, van Eickels M, Sahin K, Zell E, Ageno W, Turpie AGG. Mantovani LG, et al. Among authors: monje d. Eur J Intern Med. 2019 Mar;61:29-33. doi: 10.1016/j.ejim.2018.10.002. Epub 2018 Oct 19. Eur J Intern Med. 2019. PMID: 30342973 Free article.
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
Kreutz R, Mantovani LG, Haas S, Monje D, Schneider J, Bugge JP, Gebel M, Tamm M, Ageno W, Turpie AGG. Kreutz R, et al. Among authors: monje d. Thromb Res. 2019 Apr;176:125-132. doi: 10.1016/j.thromres.2019.02.010. Epub 2019 Feb 13. Thromb Res. 2019. PMID: 30825694 Free article. Clinical Trial.
Real life studies and good clinical practice - Authors' reply.
Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Ageno W, et al. Among authors: monje d. Lancet Haematol. 2016 Apr;3(4):e160-1. doi: 10.1016/S2352-3026(16)00027-2. Lancet Haematol. 2016. PMID: 27063973 No abstract available.
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
Haas S, Mantovani LG, Kreutz R, Monje D, Schneider J, Zell ER, Tamm M, Gebel M, Bugge JP, Ageno W, Turpie AGG. Haas S, et al. Among authors: monje d. Res Pract Thromb Haemost. 2021 Mar 20;5(3):426-438. doi: 10.1002/rth2.12489. eCollection 2021 Mar. Res Pract Thromb Haemost. 2021. PMID: 33870028 Free PMC article.
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Fox KAA, Anand SS, Aboyans V, Cowie MR, Debus ES, Zeymer U, Monje D, Vogtländer K, Lawatscheck R, Gay A. Fox KAA, et al. Among authors: monje d. Am Heart J. 2020 Apr;222:166-173. doi: 10.1016/j.ahj.2020.01.015. Epub 2020 Jan 28. Am Heart J. 2020. PMID: 32092505 Clinical Trial.
13 results